Driving Tibsovo Market Growth in 2025: The Role of Rising Acute Myeloid Leukemia Cases Driving Market Growth Due To High Mortality And Increasing Awareness

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Tibsovo Market Size Growth Forecast: What to Expect by 2025?
The market size of Tibsovo has significantly expanded over the past few years. The market value is expected to increase from $0.99 billion in 2024 to $1.08 billion in 2025, with a compound annual growth rate (CAGR) of 9.7%. The historic period's growth can be associated with the escalating cases of acute myeloid leukemia (AML), the increasing number of IDH1 mutations in cancer patients, the growing consciousness about targeted cancer treatments, and the enhanced research and development in the field of oncology.

How Will the Tibsovo Market Size Evolve and Grow by 2029?
The market size of Tibsovo is forecasted to expand significantly in the upcoming years, reaching $1.55 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 9.4%. The surge during the forecast period can be credited to heightened demand for specialized cancer treatment protocols, increased acceptance of IDH1 inhibitors, the growth of biopharmaceutical R&D, and supportive regulatory greenlights. The forecast period is also foreseen to witness trends such as the progression in precision oncology, strategic partnerships, and collaborations, forward strides in the development of small-molecule drugs, regulatory endorsement, and improvement in treatment procedures.

View the full report here:
https://www.thebusinessresearchcompany.com/report/tibsovo-global-market-report

What Drivers Are Propelling the Growth of Tibsovo Market Forward?
The escalating incidence of acute myeloid leukemia is predicted to drive the expansion of the tibosovo market. Acute myeloid leukemia (AML) is a rapidly advancing blood and bone marrow cancer that affects the production of blood cells, the immune system, and overall health. The increasing number of AML cases is largely attributed to the global rise in the elderly population as AML chiefly affects older adults. With higher life expectancies, more people are entering the age bracket most vulnerable to this type of leukemia. Tibsovo acts on acute myeloid leukemia by focusing on IDH1-mutated cancer cells, reducing abnormal cell proliferation, curbing disease advancement, increasing treatment responsiveness, and enhancing survival rates by recovering regular blood cell generation. For example, in February 2023, a report by the Australian non-profit organization, the Leukemia Foundation, projected that from 2022 to 2035, over 7,000 children, 6,000 young adults, and 108,000 adults (aged 25-65) are anticipated to be diagnosed with blood cancers, primarily acute lymphoblastic leukemia (ALL), AML, and non-Hodgkin lymphoma. Therefore, the escalating incidence of acute myeloid leukemia is fuelling the expansion of the tibosovo market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24725&type=smp

Which Emerging Trends Are Transforming the Tibsovo Market in 2025?
Leading companies in the tibsovo market are concentrating on securing regulatory endorsements to expand the reach of their drug and preserve their position in the field of IDH1-mutated cancers. The term regulatory approvals corresponds to official consents given by health regulatory bodies, allowing the legal sale and usage of a drug to treat specific health conditions after its safety and effectiveness have been verified. For example, in October 2023, Servier Laboratoires, a pharmaceutical firm based in France, was granted approval by the European Commission for tibsovo (ivosidenib tablets), making it the primary and only IDH1-targeted therapy in Europe approved for two difficult-to-treat forms of cancer. The authorization covers its use along with azacitidine in newly diagnosed acute myeloid leukemia (AML) patients with an IDH1 R132 mutation who are not suitable for standard induction chemotherapy. It also applies to its use as a standalone therapy for adults with locally advanced or metastasized cholangiocarcinoma carrying the same mutation after undergoing at least one systemic treatment. This authorization, which comes with orphan drug designation, meets pressing unmet medical requirements, offering prospects for improved patient outcomes and quality of life.

What Are the Key Segments in the Tibsovo Market?
The tibsovo market covered in this report is segmented -

1) By Product: Tablets, Capsules, Combination Therapy, Injectable Forms
2) By Drug Administration: Oral Administration, Intravenous Administration
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Cancer Treatment, Acute Myeloid Leukemia, Chemotherapy, Targeted Therapy
5) By End User: Hospitals, Specialty Clinics, Research Institutions, Homecare Settings

Subsegments:
1) By Tablets, Oral Tablets, Extended-Release Tablets
2) By Capsules, Soft Gel Capsules, Hard Gel Capsules
3) By Combination Therapy, Tibsovo + Chemotherapy Agents, Tibsovo + Targeted Therapy Agents
4) By Injectable Forms, Intravenous Injection, Subcutaneous Injection

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24725&type=smp

Who Are the Key Players Shaping the Tibsovo Market's Competitive Landscape?
Major companies operating in the tibsovo market are Servier Laboratoires, Agios Pharmaceuticals

What Geographic Markets Are Powering Growth in the Tibsovo Market?
North America was the largest region in the tibsovo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tibsovo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24725

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.